GRAND PHARMA (00512) appears at BIOHK2025 Go Global strategy to open up the global innovative drug market.

Recently, the Hong Kong International Biotechnology Forum and Exhibition (BIOHK) 2025 grandly opened, with many industry scientists, business leaders, investors, etc. gathering together to discuss the future development of biotechnology. The Hong Kong stock technology innovative international pharmaceutical company, GRAND PHARMA (00512), was invited to participate in this conference, and in the segment of the biotechnology leadership roundtable forum with the theme "Global Leaders Discussing the Future of Biomedicine," shared their experiences and thoughts on the company's global strategy for core drug globalization with international peers. BIOHK 2025 is a well-known biotechnology forum and exhibition in Asia, which has become an important platform for industry professionals to exchange and discuss cutting-edge topics in the field of biotechnology. The conference is based in Hong Kong, an important base for the internationalization journey of Chinese local companies, providing assistance for the international development of many companies. As a global leader in core drugs, GRAND PHARMA shared its unique core drug globalization development strategy at this forum, firmly implementing the "Go Global" globalization strategy to promote the sustained release of innovative product value through its global research, production, and sales chain layout. The benefits of innovative strategies are steadily realized, promoting the "dual-reporting" in China and the United States Against the background of the benefits of industrial innovation and upgrading of China Meheco Group, the recognition of Chinese innovative drugs globally is continuously increasing. Reliance on innovative drugs going global to seek larger market spaces has become an important choice for pharmaceutical companies. Research by China Merchants Bank shows that the global expansion of Chinese innovative drugs is accelerating. Taking the largest event in the global oncology treatment field, the American Society of Clinical Oncology (ASCO), as an example, the number of oral reports by Chinese pharmaceutical companies at ASCO has increased from 25 in 2023 to 84 in 2025, and the amount of innovative drug international licensing transactions in the first half of 2025 has exceeded that of the entire 2024, demonstrating strong innovative strength. As one of the benchmarks for the upgrade and development of Chinese pharmaceutical companies, GRAND PHARMA is expanding to a broader global market with its technological innovation, and the company's strong core competitiveness has made it more calm and forward-looking in its layout of innovative drugs going global. The simultaneous advancement of GRAND PHARMA's "product globalization" and "industry globalization" has already achieved breakthroughs in the overseas research, development, production, and sales of core drugs, laying a solid foundation for establishing local roots overseas. In terms of products, GRAND PHARMA is continuously expanding the global market presence of its marketed drugs. Its innovative core drug Yttrium-90 [90Y] microsphere injections have been used by over 150,000 people in more than 50 countries globally. This product is the first and only selective internal radiation therapy product approved by the US FDA for dual indications of unresectable HCC and liver metastases from colorectal cancer. Recently, this product also received CE mark certification for new indications in Europe, for the treatment of liver cancer patients, expanding from the previous indications of unresectable hepatocellular carcinoma (HCC) and unresectable metastatic colorectal cancer (mCRC) to multiple indications such as unresectable intrahepatic cholangiocarcinoma (ICC), liver metastases due to neuroendocrine tumors (mNET) or other metastases, covering a more comprehensive classification of primary liver cancer and secondary liver metastases, with the corresponding global market space expected to double in size. In terms of research and development, GRAND PHARMA focuses on the integrated treatment concept of tumor diagnosis and treatment. Currently, the company has 15 innovative products in the research and development registration stage, covering 5 types of radioisotopes including Ga-68, Lu-177, I-131, Y-90, and Zr-89, targeting 8 types of cancer including liver cancer, prostate cancer, kidney cancer, and brain cancer. For drugs in the clinical research stage, the company is firmly promoting the "dual-reporting" strategy between China and the United States. Innovative radiolabeled drugs for the treatment of prostate cancer (RDC) TLX591 and innovative RDC drugs for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) such as ITM-11 have already been included in international multi-center phase III clinical trials, laying a foundation for the smooth access of the company's innovative products to multiple regions globally. In fact, through years of global innovation layout, GRAND PHARMA can independently lead the research and development, clinical advancement, and registration application of innovative products overseas, which will be an important advantage for the company in the subsequent process of promoting overseas clinical research of innovative drugs. Furthermore, several innovative products from the company are continuously appearing at international authoritative conferences, further highlighting the innovative drug brand of GRAND PHARMA. In 2025, two abstracts on Yttrium-90 were accepted at ASCO, and 15 research results were selected for the 2025 Asia-Pacific Primary Liver Cancer Expert Conference. In addition, the company's own innovative RDC drug, GPN02006, also received an oral presentation at the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) in North America. The achievements of these series of internationalized innovative products signify that the global layout under the drive of innovation by GRAND PHARMA has been successful. With the steadfast implementation of the "Go Global" globalization strategy, GRAND PHARMA will accelerate the global market acceptance of innovative achievements with higher research and development efficiency in the future, and will continue to enhance the influence and competitiveness of Chinese innovative drugs on the international stage with high standards of clinical data and product quality. The full-chain layout establishes the advantage of going global, setting sail to create long-term growth Supported by independent and controllable research and development bases and self-built production facilities, GRAND PHARMA's global development momentum is strong. The company has currently established research and development centers centered around Boston and Chengdu, production centers centered around Boston, Frankfurt, Singapore, and Chengdu, and has achieved a sales network for core drugs covering over 50 countries and regions globally, making it the only international enterprise to achieve full coverage of early research, clinical trials, registration, and commercialization of core drugs. In terms of production, GRAND PHARMA has perfected its production facilities to the highest international standards, ensuring stable global product supply while also fully guaranteeing product quality. The Chengdu radioisotope research and production base officially put into operation by the company in June this year has established a world-class research and production quality and operation system, being one of the most comprehensive in terms of types of isotopes and highest in terms of automation level worldwide, and is also the world's first "zero radiation" intelligent nuclear drug factory as well as the first global complete closed-loop platform for the nuclear drug industry. In addition to its advantage in core drugs, GRAND PHARMA has carried out global innovation layouts in its major business segments. The company has established 5 research technology platforms and 8 research centers globally, covering multiple business sectors including nuclear drug anti-tumor diagnosis and treatment, cardiovascular and cerebrovascular precision interventional diagnosis and treatment, and pharmaceutical technology. With 133 research projects and 42 innovation projects in reserve, distributed across various stages from pre-clinical to new drug market application, forming a good domino effect. This overseas localization layout spanning key links such as research and production not only equips GRAND PHARMA's innovative drugs with multiple advantages such as cost, efficiency, and compliance in international competition but also allows the company to deeply understand and respond to the unmet medical needs of global patients, laying an irreplaceable solid foundation for long-term rooting in overseas markets. As the future deepening of GRAND PHARMA's "Go Global" international strategy continues, the company will not only create its own pharmaceutical brand but also achieve in-depth market development and value exploration on a global scale.